Home > Qtrly Results > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Quarterly Results Analysis [Sep2025]

GLENMARK PHARMACEUTICALS is part of below Screeners ↓
Best Quarterly Growth Mid Cap Stocks
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results

GLENMARK PHARMACEUTICALS Quarterly Results

Consolidated Sep2025
UnAudited
Jun2025
UnAudited
Mar2025
UnAudited
Dec2024
UnAudited
Sep2024
UnAudited
Jun2024
UnAudited
Mar2024
UnAudited
Dec2023
UnAudited
Revenues ₹6,047 Cr ₹3,264 Cr ₹3,256 Cr ₹3,388 Cr ₹3,434 Cr ₹3,244 Cr ₹3,063 Cr ₹2,507 Cr
Expenses ₹3,687 Cr ₹2,684 Cr ₹2,695 Cr ₹2,787 Cr ₹2,832 Cr ₹2,656 Cr ₹2,559 Cr ₹2,715 Cr
Operating Income ₹2,360 Cr ₹581 Cr ₹561 Cr ₹600 Cr ₹602 Cr ₹588 Cr ₹504 Cr ₹-209 Cr
Other Income ₹201 Cr ₹26 Cr ₹12 Cr ₹31 Cr ₹39 Cr ₹31 Cr ₹773 Cr ₹45 Cr
Interest ₹66 Cr ₹58 Cr ₹67 Cr ₹52 Cr ₹48 Cr ₹40 Cr ₹149 Cr ₹134 Cr
Depreciation ₹141 Cr ₹130 Cr ₹125 Cr ₹123 Cr ₹120 Cr ₹118 Cr ₹151 Cr ₹147 Cr
Profit Before Tax ₹967 Cr ₹96 Cr ₹8 Cr ₹456 Cr ₹473 Cr ₹462 Cr ₹531 Cr ₹-521 Cr
Profit After Tax ₹610 Cr ₹47 Cr ₹4 Cr ₹348 Cr ₹354 Cr ₹340 Cr ₹-1,239 Cr ₹-450 Cr
EPS ₹21.63 ₹1.66 ₹0.16 ₹12.33 ₹12.55 ₹12.06 ₹-43.17 ₹-12.45
Industry Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS 1.4% 6.9% 26.8%
SUN PHARMACEUTICAL INDUSTRIES -0.7% 7.4% -0.1%
DIVIS LABORATORIES -0.1% -4.8% 3.3%
CIPLA -0.6% 1.2% NA
TORRENT PHARMACEUTICALS 2.2% 6.3% 11.4%
DR REDDYS LABORATORIES 1.5% 6.4% 4.8%
MANKIND PHARMA -1.9% -6.8% -15.7%
ZYDUS LIFESCIENCES -0.8% -3.9% -4%
LUPIN 0.5% 4.7% 0.5%

GLENMARK PHARMACEUTICALS Quarterly Revenues

Revenues
Q-o-Q

85.23 %

Y-o-Y

76.10 %

Quarters Revenues % Change
Sep2025 ₹6,047 Cr
85.23
Jun2025 ₹3,264 Cr
0.25
Mar2025 ₹3,256 Cr
-3.88
Dec2024 ₹3,388 Cr
-1.35
Sep2024 ₹3,434 Cr
5.84
Jun2024 ₹3,244 Cr
5.92
Mar2024 ₹3,063 Cr
22.19
Dec2023 ₹2,507 Cr -

GLENMARK PHARMACEUTICALS Quarterly Operating Profit

Operating Profit
Q-o-Q

306.45 %

Y-o-Y

292.01 %

Quarters Operating Profit % Change
Sep2025 ₹2,360 Cr
306.45
Jun2025 ₹581 Cr
3.47
Mar2025 ₹561 Cr
-6.53
Dec2024 ₹600 Cr
-0.28
Sep2024 ₹602 Cr
2.33
Jun2024 ₹588 Cr
16.63
Mar2024 ₹504 Cr
Positive
Dec2023 ₹-209 Cr -
Operating Margins
Q-o-Q

119.46 %

Y-o-Y

122.59 %

Quarters Operating Margin% % Change
Sep2025 39.02%
119.46
Jun2025 17.78%
3.19
Mar2025 17.23%
-2.77
Dec2024 17.72%
1.08
Sep2024 17.53%
-3.31
Jun2024 18.13%
10.08
Mar2024 16.47%
Positive
Dec2023 -8.32% -

GLENMARK PHARMACEUTICALS Quarterly Profit After Tax

Profit After Tax(PAT)
Q-o-Q

1,199.54 %

Y-o-Y

72.20 %

Quarters Profit After Tax % Change
Sep2025 ₹610 Cr
1,199.54
Jun2025 ₹47 Cr
971.46
Mar2025 ₹4 Cr
-98.74
Dec2024 ₹348 Cr
-1.82
Sep2024 ₹354 Cr
4.19
Jun2024 ₹340 Cr
Positive
Mar2024 ₹-1,239 Cr
Negative
Dec2023 ₹-450 Cr -
PAT Margins
Q-o-Q

601.39 %

Y-o-Y

-2.13 %

Quarters PAT Margin(%) % Change
Sep2025 10.1 %
601.39
Jun2025 1.44 %
1,007.69
Mar2025 0.13 %
-98.73
Dec2024 10.27 %
-0.48
Sep2024 10.32 %
-1.62
Jun2024 10.49 %
Positive
Mar2024 -40.44 %
Negative
Dec2023 -17.94 % -

GLENMARK PHARMACEUTICALS Quarterly Earnings Per Share (EPS)

EPS
Q-o-Q

1,203.01 %

Y-o-Y

72.35 %

Quarters EPS % Change
Sep2025 ₹21.63
1,203.01
Jun2025 ₹1.66
937.50
Mar2025 ₹0.16
-98.70
Dec2024 ₹12.33
-1.75
Sep2024 ₹12.55
4.06
Jun2024 ₹12.06
Positive
Mar2024 ₹-43.17
Negative
Dec2023 ₹-12.45 -

You may also like the below Video Courses